Share
3,236 Posts.
lightbulb Created with Sketch. 275
clock Created with Sketch. 11/07/17
16:51
Share
Originally posted by monti901
↑
I think we both agree IMP (regardless of your views of Mark and his salary) that ANP is greatly undervalued considering its position, with two drugs passed phase 2 clinical trials, IND approval for 1102 due within two weeks, potential for non diluted funding for a phase 2b R-MS trial from a US federal agency, a new 1102 treatment (DMD), a cash injection from Australian Ethical Investment and of course being in discussions for a potential 1103 partnership. The market at this stage has placed no value at all in ANP's prospects, however I believe that this will change rapidly as further announcements are made in the near future. The endless frustrated narrative of individuals on this forum I also believe has greatly contributed to the shareprice demise and has scared away potential retail investors. The recent annoucements in my view were very positive. It was dissapointing to read others putting a negative spin on what would otherwise have given the SP a much needed leg up. Looking forwarding to upcoming annoucements and a move back to true SP value.. clearly those who bought in at 10 cents plus (like myself) are disappointed in the SP but with fundamentals unchanged and the technology further advanced, the current share price dip is a great opportunity for others to buy in to a greatly undervalued company...
Expand
Monti9 are you sure about cash injection???before 30 September 2017 to commence the clinical trial for ATL1102 in DMD."
